New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT05981703
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-26808 (HPK1 inhibitor) and tislelizumab (anti-PD-1 antibody)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug will work. Side effects are possible, and the drug may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010-3012, United States
-
Hangzhou First Peoples Hospital
RECRUITINGHangzhou, Zhejiang, 310006, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150000, China
-
Harbour Cancer and Wellness
RECRUITINGAuckland, 1023, New Zealand
-
Health New Zealand Te Whatu Ora Lakes Rotorua Hospital
RECRUITINGRotorua, 3010, New Zealand
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, 430079, China
-
Icahn School of Medicine At Mount Sinai
RECRUITINGNew York, New York, 10029-6504, United States
-
Icon Cancer Centre Kurralta Park
RECRUITINGKurralta Park, South Australia, SA 5037, Australia
-
Jining No1 Peoples Hospital West Branch
RECRUITINGJining, Shandong, 272000, China
-
John Theurer Cancer Center Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, WA 6009, Australia
-
Macquarie University
RECRUITINGNorth Ryde, New South Wales, NSW 2109, Australia
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213-2933, United States
-
Shanghai East Hospital Branch Hospital
RECRUITINGShanghai, Shanghai Municipality, 200123, China
-
Shanghai Pulmonary Hospital
COMPLETEDShanghai, Shanghai Municipality, 200433, China
-
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
RECRUITINGChengdu, Sichuan, 610071, China
-
Southside Cancer Care
COMPLETEDMiranda, New South Wales, NSW 2228, Australia
-
Sylvester Cancer Center, University of Miami
RECRUITINGMiami, Florida, 33136, United States
-
Taizhou Hospital of Zhejiang Province (East)
COMPLETEDTaizhou, Zhejiang, 317004, China
-
The First Affiliated Hospital of Anhui Medical Universitygaoxin Branch
RECRUITINGHefei, Anhui, 230022, China
-
The First Hospital of China Medical University Hunnan Branch
RECRUITINGShenyang, Liaoning, 110167, China
-
The University of Texas Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4009, United States
-
Tongji Hospital,Tongji Medical College of Hustsino French New City Branch
RECRUITINGWuhan, Hubei, 430101, China
-
University of Michigan Health System
RECRUITINGAnn Arbor, Michigan, 48109-5316, United States
-
University of Southern California Norris Comprehensive
RECRUITINGLos Angeles, California, 90033, United States
-
Yale University Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520-8028, United States
-
Yantai Yuhuangding Hospital
RECRUITINGYantai, Shandong, 264000, China